Theratechnologies (THTX) said Wednesday it acquired exclusive Canadian rights to two investigational RNA-targeted medicines from Ionis Pharmaceuticals (IONS).
The agreement includes olezarsen, which is being evaluated for familial chylomicronemia syndrome and severe hypertriglyceridemia, and donidalorsen, which is being studied for hereditary angioedema treatment.
Theratechnologies will pay Ionis $10 million upfront, with potential milestone payments of up to $12.75 million and tiered double-digit royalties on net sales.
The company said it would oversee regulatory approvals in Canada while Ionis would remain the primary manufacturer. The agreement extends until commercialization ceases or upon earlier termination.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.